INAB Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -- compared to IN8bio's net margin of 14.23%. IN8bio's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 6.29%.

IN8bio has a consensus price target of --, signalling upside risk potential of 1809.16%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 49.31%. Given that IN8bio has higher upside potential than Biomarin Pharmaceutical, analysts believe IN8bio is more attractive than Biomarin Pharmaceutical.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. IN8bio's net income of -$7.1M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, IN8bio's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus 4.69x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Ensysce Biosciences has a net margin of -- compared to IN8bio's net margin of --. IN8bio's return on equity of -- beat Ensysce Biosciences's return on equity of --.

IN8bio has a consensus price target of --, signalling upside risk potential of 1809.16%. On the other hand Ensysce Biosciences has an analysts' consensus of -- which suggests that it could grow by 1170.24%. Given that IN8bio has higher upside potential than Ensysce Biosciences, analysts believe IN8bio is more attractive than Ensysce Biosciences.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ensysce Biosciences has a beta of 0.598, suggesting its less volatile than the S&P 500 by 40.229%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ensysce Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. Ensysce Biosciences pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than Ensysce Biosciences quarterly revenues of --. IN8bio's net income of -$7.1M is lower than Ensysce Biosciences's net income of $661.8K. Notably, IN8bio's price-to-earnings ratio is -- while Ensysce Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus -- for Ensysce Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

GlycoMimetics has a net margin of -- compared to IN8bio's net margin of --. IN8bio's return on equity of -- beat GlycoMimetics's return on equity of --.

IN8bio has a consensus price target of --, signalling upside risk potential of 1809.16%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 327.9%. Given that IN8bio has higher upside potential than GlycoMimetics, analysts believe IN8bio is more attractive than GlycoMimetics.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.069%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than GlycoMimetics quarterly revenues of --. IN8bio's net income of -$7.1M is higher than GlycoMimetics's net income of -$9.8M. Notably, IN8bio's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.

Genprex has a net margin of -- compared to IN8bio's net margin of --. IN8bio's return on equity of -- beat Genprex's return on equity of --.

IN8bio has a consensus price target of --, signalling upside risk potential of 1809.16%. On the other hand Genprex has an analysts' consensus of -- which suggests that it could grow by 724.18%. Given that IN8bio has higher upside potential than Genprex, analysts believe IN8bio is more attractive than Genprex.

IN8bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genprex has a beta of -1.377, suggesting its less volatile than the S&P 500 by 237.675%.

IN8bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio pays -- of its earnings as a dividend. Genprex pays out -- of its earnings as a dividend.

IN8bio quarterly revenues are --, which are smaller than Genprex quarterly revenues of --. IN8bio's net income of -$7.1M is lower than Genprex's net income of -$4.3M. Notably, IN8bio's price-to-earnings ratio is -- while Genprex's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio is -- versus -- for Genprex. Usually stocks with elevated PS ratios are considered overvalued.